Infectious Disease · 1955
Salk Inactivated Polio Vaccine Field Trial (Francis Report)
An Evaluation of the 1954 Poliomyelitis Vaccine Trials
Poliomyelitis paralyzed tens of thousands of children in the United States each summer through the late 1940s and early 1950s. The 1952 epidemic was the worst on record, with nearly 58,000 reported cases. Parents kept children away from public swimming pools and movie theaters. Iron lung wards filled. The National Foundation for Infantile Paralysis, founded by Franklin Roosevelt, had been funding polio research since 1938, and by 1952 Jonas Salk at the University of Pittsburgh was developing a formalin-inactivated vaccine using all three poliovirus serotypes grown in monkey kidney cells.
The 1954 field trial was organized by the National Foundation and evaluated by Thomas Francis Jr. at the University of Michigan, who had no role in developing the vaccine. This external evaluation was deliberate: it separated the judgment from the inventor's interest. The trial enrolled approximately 1.8 million children across the United States, Canada, and Finland, divided among vaccinated, placebo, and unvaccinated control groups. Children, physicians, and evaluators in the placebo arm were blinded to assignment.
Francis presented his findings on April 12, 1955, at Rackham Auditorium in Ann Arbor. The vaccine was 80 to 90 percent effective against paralytic polio, with the highest protection against the most severe bulbar and spinal forms. The results were broadcast live on radio and television. Within two hours of the announcement, the U.S. government granted licensure. Manufacturers had vaccine ready to ship; distribution began the same afternoon.
The immediate public health effect was measurable. Paralytic polio cases in the United States fell sharply from the 1952 peak in the years that followed. Albert Sabin's live attenuated oral vaccine, which was easier to administer and produced intestinal immunity blocking transmission, began supplementing the Salk vaccine in the early 1960s. Wild-type polio transmission was eliminated from the United States by 1979.
The 1954 trial's design influenced vaccine evaluation methodology for decades. A placebo-controlled, observer-blinded trial with an independent evaluator, in a population of nearly two million, set expectations for rigor that regulatory agencies later codified. Salk was not listed as an author on the Francis report, a deliberate choice to maintain the evaluator's independence. The Global Polio Eradication Initiative, launched in 1988, reduced wild poliovirus circulation worldwide to a handful of countries by the 2020s, building on the immunological and logistical framework the 1955 licensure established.
Key People
- Jonas Salk — Virologist who developed the inactivated poliovirus vaccine.
- Thomas Francis Jr. — Epidemiologist who independently evaluated the 1954 trial results.
- Albert Sabin — Virologist who developed the oral live attenuated vaccine used from the early 1960s.
- Basil O'Connor — President of the National Foundation for Infantile Paralysis; organized the trial funding.
Am J Public Health Nations Health. 1955;45(5 Pt 2):1-63
Related landmarks
- 1960 · Sabin Oral Live-Attenuated Polio Vaccine (Infectious Disease)
- 1965 · Discovery of the hepatitis B virus (Australia antigen) (Infectious Disease)
- 1981 · First report of AIDS (Pneumocystis pneumonia cluster) (Infectious Disease)
- 1928 · Fleming's discovery of penicillin (Infectious Disease)